Combination Immunotherapy for Cancer Treatment—2nd Edition
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: 25 September 2026 | Viewed by 1336
Editor
Interests: cancer immunotherapy; proteomics; metabolomics; diabetes; COPD; HIV
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue represents a continuation of our previous Special Issue titled “Combination Immunotherapy for Cancer Treatment” (https://www.mdpi.com/journal/cancers/special_issues/P16946Y131).
This Special Issue will be dedicated to exploring the fascinating field of combination immunotherapy and its potential to revolutionize cancer treatment. In recent years, immunotherapy has emerged as an exciting approach in the fight against cancer, harnessing the power of the immune system to target and destroy cancer cells. However, single-agent immunotherapy has shown limitations in achieving complete and durable responses in all patients. That is where combination immunotherapy comes into play. By combining different immunotherapeutic agents, such as immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell transfer, researchers and clinicians aim to enhance the effectiveness of treatment and overcome resistance mechanisms. Original research works and review articles covering the aforementioned or any novel biologics-mediated cancer treatment or immunotherapy will be considered for this Special Issue.
Dr. Carlos Alberto Barrero
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- immune checkpoint inhibitor
- cancer vaccine
- novel cancer therapy
- treatment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
